Clinical Trial

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-13; most recent amendment 2026-06-16.
Trial Details
NCT Number NCT07231952
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: AbbVie, Eli Lilly and Company
Conditions Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Enrollment 40 participants
Start Date 2025-11-11
Primary Completion 2028-04-11 (estimated)
Study Completion 2028-04-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-17